Luteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering in Women at Risk of OHSS

San Carlo Public Hospital, Potenza, Italy

Status: Completed

Conditions: Ovarian Hyperstimulation Syndrome

Treatments: Drug: recombinant LH

Study type: Observational

Funder types: Other

Identifiers

NCT02200952

Luveris75UI

Details and patient eligibility

About

The purpose of this study is to prove that luteal phase supplementation with recombinant LH can solve the luteal phase deficiency after Gnrh agonist oocytes triggering in women at risk of OHSS

Full description

The investigators enrolled patients, undergoing controlled ovarian stimulation for an IVF/ICSI cycles, who on the day of oocytes triggering were at risk of OHSS.

These patients had an estradiol > 4000 pg/ml and more than 24 follicles with a diameter greater than 12 mm.

The investigators used 0,2 mg of triptorelin for the oocytes triggering and supplemented the luteal phase with recombinant LH at a dose of 75 UI twice/day for 10 days and vaginal gel progesterone and oral oestradiol for 14 days The investigators measured bhCG at 14 days from the pick up. In case of positive bhCG we have defined the IVF/ICSI outcome: Pregnancy Rate and Implantation Rate.

Enrollment: 16 patients

Sex: Female

Ages: 18 to 43 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with an oestradiol > 4000 pg/ml on the oocytes triggering day
• patient with more than 24 follicles of diameter greater than 12 mm on the oocytes triggering day

Exclusion criteria

• patients with no risk of OHSS on the oocytes triggering day
• patients with an oestradiol < 4000 pg/ml on the oocytes triggering day
• patient with less than 24 follicles of diameter greater than 12 mm on the oocytes triggering day

Trial design

16 participants in 1 patient group

Patients at risk of OHSS

Description:

Patients at risk of OHSS on the oocytes triggering day with an oestradiol \> 4000pg/ml or a number of follicles greater than 24 of a diameter greater than 12 mm

Treatment:

Drug: recombinant LH